This is a multi-centre, single- arm, non-randomized, open-label phase 1/2 clinical trial which enables dosing of the fellow eyes of patients who received VGR-R01 administration in previous studies.
Participants received VGR-R01 administration in the VGR-R01-001 or VGR-R01-101 studies.
Able to provide informed consent and comply with requirements of the study;
Hand Motion ≤ BCVA ≤ 75 ETDRS letters in the second treated eye.
Have insufficient viable retinal photoreceptor cells based on investigator's decision;
Have current ocular or periocular infections, or endophthalmitis;
Have any significant ocular disease/disorder other than BCD, including age-related macular degeneration, diabetic retinopathy, optic neuropathy, significant lens opacity, glaucoma, uveitis, retinal detachment, etc;
Have intraocular surgery history except cataract surgery in the study eye;